DEC 14, 2017 08:00 AM PST

WEBINAR: Emergence of Clinical Proteomics: Identifying and developing actionable protein biomarkers for use in clinical research.

SPONSORED BY: Thermo Fisher Scientific
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • President of Proteomics, NantOmics
    Biography
      Todd Hembrough, PhD is the President, Proteomics at NantOmics where he oversees R&D, operations, and the clinical proteomics laboratory. Todd obtained his Ph.D. in Biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, Todd was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways. Todd later became the Chief Scientific Officer and Head of R&D at OncoPlex Diagnostics and Expression Pathology where he helped lead the development and commercial launch of the first quantitative proteomic assays performed on formalin-fixed, paraffin-embedded tissue.
    • Manager, Assay Development, NantOmics
      Biography
        Maryann Vogelsang, PhD leads the assay development team, and drives the implementation and delivery of NantOmics' mass spectrometry (MS)-based assay development pipeline for both R&D and clinical proteomics laboratories. Maryann earned her PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles. Prior to NantOmics, Maryann established a CLIA compliant laboratory that offered both ELISA- and MS-based clinical assays. She has over a decade of experience in translational medicine utilizing the mass spectrometry platform, and spent a significant part of her career as a scientist developing workflows that facilitate proteomics biomarker discovery and validation processes at the Thermo Fisher Scientific BRIMS Center.

      Abstract:

      DATE: December 14, 2017
      TIME: 08:00am PST, 11:00am EST, 4:00pm BST, 5:00pm CEST

      The benefits of genomic analysis are well understood, however, the majority of patients do not harbor druggable alterations in their genomes and thus are not candidates for targeted therapies.  In patients whose tumors lack genomic biomarkers for targeted therapies or have developed resistance, clinical proteomics is identifying protein biomarkers for therapies that are benefitting patients—thus fueling the emergence of proteogenomics. 

      We have built more than 250 quantitative proteomic assays for relevant oncology biomarkers expressed in solubilized, formalin-fixed, paraffin-embedded tumor samples using selected reaction monitoring mass spectrometry.  This webinar will cover the assay development pipeline utilized to bring these quantitative proteomic markers into our CAP-CLIA laboratory.  Starting from a targeted-discovery initiative to the analytical validation of our multiplexed SRM methods, we will discuss the metrics used to validate our assays. 

      Additionally, this webinar will introduce the impact these developed markers have on clinical research, including the retrospective analyses of HER2 proteomic expression in adjuvant and metastatic breast cancer and in advanced gastric cancer.  The HER2 proteomic expression levels correlated with response to trastuzumab.  From this correlation, we were able to identify a proteomic cut-off value of response.  This potential benefit extended to donors identified as non-breast/non-gastric cancer patients who overexpressed HER2 and who subsequently responded to HER2-targeted therapy.

      Key Learning Objectives:

      • Metrics used to analytically validate a multiplexed proteomic LC-MS assay.
      • Workflows and processes used in working with Liquid Tissue®.
      • The clinical impact on delivering much needed biomarkers of therapeutic response.

      Show Resources
      You May Also Like
      MAY 16, 2019 04:00 PM CEST
      C.E. CREDITS
      MAY 16, 2019 04:00 PM CEST
      DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
      AUG 27, 2019 09:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 09:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      NOV 18, 2019 07:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 18, 2019 07:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
      JUN 05, 2019 05:00 PM CEST
      C.E. CREDITS
      JUN 05, 2019 05:00 PM CEST
      DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
      SEP 05, 2019 04:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 04:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      JUN 19, 2019 10:00 AM PDT
      JUN 19, 2019 10:00 AM PDT
      DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
      Loading Comments...
      Show Resources